WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206069
CAS#: 1303607-07-9
Description: MI-773 is a new small molecule inhibitor of the MDM2-p53 interaction, binds to MDM2 with high affinity (Ki=0.88 nM) and blocks the p53-MDM2 interaction. MI-773 is an isomer of MI-77301 (SAR405838).
MedKoo Cat#: 206069
Name: MI-773
CAS#: 1303607-07-9
Chemical Formula: C29H34Cl2FN3O3
Exact Mass: 561.19613
Molecular Weight: 562.51
Elemental Analysis: C, 61.92; H, 6.09; Cl, 12.60; F, 3.38; N, 7.47; O, 8.53
MI-773, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Related CAS #: 1303607-07-9 1303607-60-4
Synonym: MI773; MI-773; MI 773
IUPAC/Chemical Name: (2'R,3S,4'S,5'R)-6-Chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-1,2-dihydro-N-(trans-4-hydroxycyclohexyl)-2-oxospiro[3H-indole-3,3'-pyrrolidine]-5'-carboxamide
InChi Key: IDKAKZRYYDCJDU-HEVVSWJASA-N
InChi Code: InChI=1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)/t16-,17-,22-,23+,25-,29+/m1/s1
SMILES Code: O=C([C@H](N[C@@H]1CC(C)(C)C)[C@H](C2=CC=CC(Cl)=C2F)[C@]31C(NC4=C3C=CC(Cl)=C4)=O)N[C@H]5CC[C@H](O)CC5
The following data is based on the product molecular weight 562.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S,
Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE. Ablation of Cancer
Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in
Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 Mar 1;25(5):1588-1600. doi:
10.1158/1078-0432.CCR-17-2730. Epub 2018 Nov 29. PubMed PMID: 30498096; PubMed
Central PMCID: PMC6397688.
2: Wong JH, Alfatah M, Sin MF, Sim HM, Verma CS, Lane DP, Arumugam P. A yeast
two-hybrid system for the screening and characterization of small-molecule
inhibitors of protein-protein interactions identifies a novel putative
Mdm2-binding site in p53. BMC Biol. 2017 Nov 9;15(1):108. doi:
10.1186/s12915-017-0446-7. PubMed PMID: 29121928; PubMed Central PMCID:
PMC5680816.
3: Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, Yi JS,
Yang T, Yang J, Nuchtern JG. Novel MDM2 inhibitor SAR405838 (MI-773) induces
p53-mediated apoptosis in neuroblastoma. Oncotarget. 2016 Dec
13;7(50):82757-82769. doi: 10.18632/oncotarget.12634. PubMed PMID: 27764791;
PubMed Central PMCID: PMC5347730.
4: Nör F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI,
Sant'Ana Filho M, Wang S, Nör JE. Therapeutic Inhibition of the MDM2-p53
Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res.
2017 Feb 15;23(4):1036-1048. doi: 10.1158/1078-0432.CCR-16-1235. Epub 2016 Aug
22. PubMed PMID: 27550999; PubMed Central PMCID: PMC5315632.
5: Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME,
Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör
JE. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res.
2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2.
PubMed PMID: 26936915; PubMed Central PMCID: PMC4947417.
